

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT

APPROVAL FOR TOUMAI SINGLE-ARM AND SINGLE-PORT LAPAROSCOPIC SURGICAL ROBOT BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Group’s self-developed Toumai Single-arm and Single-port Laparoscopic Surgical Robot (“**Toumai Single-arm**”) has been approved by the National Medical Products Administration of China (the “**NMPA**”), indicating that its overall performance, innovation level, clinical effectiveness and safety have been certified by the national authoritative regulatory department.

IMPACT ON THE COMPANY

As a leader in China’s surgical robot industry, the Company has been committed to the continuous exploration and innovation in the field of precision medicine. With its full-chain self-production and self-development capabilities, it has brought safe, effective and comprehensive intelligent surgical solutions to the surgical field in China and overseas countries. The approval of the registration application for Toumai Single-arm by the NMPA is another important milestone in the Group’s business development, which will make the Group’s product portfolio more improved and diversified. Toumai series robots will gradually achieve multi-arm, single-arm and remote integrated compatibility, which

will help enhance the competitiveness of the Company's products in the domestic and international markets. The Group will continue to adhere to medical-industrial cooperation to provide new, mature and improved diagnosis and treatment solutions to physicians and patients around the world, and keep practising our belief of "Make surgery easier, safer and less invasive".

ABOUT TOUMAI SINGLE-ARM

Toumai Single-arm is the same series of laparoscopic surgical robot as the Company's core product, Toumai Laparoscopic Surgical Robot, which can complete complex surgeries with minimally invasive approach. Toumai Single-arm is featured by a unique single-arm structure with self-developed intellectual property rights, flexible movement, as well as a convenient set-up. Its device in snake design can achieve seven degrees of freedom within a narrow space, which is more sophisticated than multi-arm robots. Toumai Single-arm performs laparoscopic surgery on a single-port basis, which has clinical values such as smaller wound, less pain and improved post-operative aesthetics compared to traditional multi-port surgeries.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 12 February 2025

As at the date of this announcement, the executive Directors are Dr. He Chao and Ms. Fang Cong, the non-executive Directors are Mr. Sun Hongbin, Mr. Chen Xinxing and Mr. Chen Chen, and the independent non-executive Directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Chung Wai Man.